A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis
Conditions
Multiple Myeloma
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.
- Trial withProthena Biosciences Inc.
- Start Date03/24/2022
- End Date06/01/2024
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Adam Boruchov, MD
- Agatha Hecht
- Alexis Walker
- Andrea Brennan
- Andrea Martelli
- Armand Russo, MD
- Brooke Chaves
- David Witt, MD
- Erica Stevens
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Justin Persico, MD
- Kathleen Fenn, MD
- Kristen Hoxie
- Madeline Santiago
- Michael Cohenuram, MD
- Natalia Neparidze, MD
- Neal Fischbach, MD
- Noffar Bar, MD
- Pawan Karanam, MD
- Sara Anastasio, RN
- Sudhanshu Mulay, MD
- Syed Bilgrami, MBBS
- Tara Anderson
- Terri Parker, MD
- Vidya Brown
- Last Updated11/11/2022
- Study HIC#2000030933